文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

内科住院营养不良风险患者的个体化营养支持:一项随机临床试验

Individualised nutritional support in medical inpatients at nutritional risk: a randomised clinical trial.
PubMed 文献 · Lancet · 2019-04-25
一句话结论对NRS 2002≥3分的内科住院患者,住院期间给予方案引导的个体化营养支持以达标蛋白质和热量目标,可降低30天不良临床结局和死亡风险。

EFFORT试验为实效性、研究者发起、开放标签、多中心研究,自8家瑞士医院纳入NRS 2002≥3分、预计住院>4天的内科非危重非手术患者2088例,1:1随机分为个体化营养支持组(由专科营养师设定目标,入院48小时内启动)与标准医院饮食组(不进行营养会诊)。主要复合终点为30天内全因死亡、入住ICU、非计划再入院、主要并发症和功能状态下降。30天时干预组232/1015(23%)发生不良临床结局,对照组272/1013(27%),校正OR 0.79(95%CI 0.64-0.97),p=0.023;干预组73/1015(7%)死亡,对照组100/1013(10%),校正OR 0.65(95%CI 0.47-0.91),p=0.011;营养支持副作用两组无差异(162[16%] vs 145[14%],校正OR 1.16[95%CI 0.90-1.51],p=0.26)。作者认为这些发现强烈支持入院时系统筛查内科住院患者营养风险,并对有风险者进行营养评估和个体化营养支持。

要点

  • 纳入标准为NRS 2002评分≥3分、预计住院>4天的内科住院患者,来自8家瑞士医院,共2088例随机分组。
  • 干预组由专科营养师设定个体化热量和蛋白质目标,营养支持不晚于入院后48小时启动;对照组仅接受标准医院饮食、无营养会诊。
  • 30天不良临床结局:干预组23%(232/1015)vs 对照组27%(272/1013),校正OR 0.79(95%CI 0.64-0.97),p=0.023。
  • 30天死亡:干预组7%(73/1015)vs 对照组10%(100/1013),校正OR 0.65(95%CI 0.47-0.91),p=0.011。
  • 营养支持副作用比例两组无显著差异:干预组16%(162)vs 对照组14%(145),校正OR 1.16(95%CI 0.90-1.51),p=0.26。

适用人群与场景

  • 内科住院患者(非危重、非手术患者),NRS 2002评分≥3分,预计住院时间>4天,来自8家瑞士医院。

诊断标准与关键阈值

  • 营养风险筛查2002(NRS 2002)评分≥3分定义为存在营养风险。

处置流程与药物剂量

  • 干预组由专科营养师定义个体化营养支持目标,营养支持不晚于入院后48小时启动,目标是达到热量和蛋白质目标。
  • 对照组接受标准医院饮食,不进行营养会诊。

研究设计与关键结果

  • 研究类型:实效性、研究者发起、开放标签、多中心随机对照试验(EFFORT),8家瑞士医院参与,2014年4月1日至2018年2月28日招募。
  • 样本量:筛查5015例,随机2088例(干预组1050例,对照组1038例);60例中途撤回知情同意(干预组35例,对照组25例)。
  • 干预实施:住院期间干预组1015例中热量目标达标800例(79%),蛋白质目标达标770例(76%)。
  • 主要复合终点(30天内全因死亡、入住ICU、非计划再入院、主要并发症、功能状态下降):干预组232/1015(23%)vs 对照组272/1013(27%),校正OR 0.79(95%CI 0.64-0.97),p=0.023。
  • 30天死亡:干预组73/1015(7%)vs 对照组100/1013(10%),校正OR 0.65(95%CI 0.47-0.91),p=0.011。
  • 营养支持副作用:干预组162/1015(16%)vs 对照组145/1013(14%),校正OR 1.16(95%CI 0.90-1.51),p=0.26,两组无显著差异。

证据类型、等级与局限

  • 证据类型:随机对照试验(RCT)。
  • 作者结论:在内科住院营养风险患者中,住院期间个体化营养支持较标准医院饮食改善了重要临床结局包括生存;这些发现强烈支持入院时系统筛查内科住院患者营养风险(不论其内科疾病),并对有风险者进行营养评估和个体化营养支持。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,应不论内科疾病种类,对所有内科住院患者在入院时系统筛查营养风险(NRS 2002),并对NRS 2002≥3分者进行营养评估和个体化营养支持。
  • 本试验中个体化营养支持由专科营养师设定热量和蛋白质目标,并在入院48小时内启动,可达到热量目标者占79%、蛋白质目标者占76%。
  • 适用人群为内科住院非危重、非手术患者,NRS 2002≥3分且预计住院>4天;本试验未纳入危重患者和手术患者。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Guidelines recommend the use of nutritional support during hospital stays for medical patients (patients not critically ill and not undergoing surgical procedures) at risk of malnutrition. However, the supporting evidence for this recommendation is insufficient, and there is growing concern about the possible negative effects of nutritional therapy during acute illness on recovery and clinical outcomes. Our aim was thus to test the hypothesis that protocol-guided individualised nutritional support to reach protein and caloric goals reduces the risk of adverse clinical outcomes in medical inpatients at nutritional risk.

METHODS: The Effect of early nutritional support on Frailty, Functional Outcomes, and Recovery of malnourished medical inpatients Trial (EFFORT) is a pragmatic, investigator-initiated, open-label, multicentre study. We recruited medical patients at nutritional risk (nutritional risk screening 2002 [NRS 2002] score ≥3 points) and with an expected length of hospital stay of more than 4 days from eight Swiss hospitals. These participants were randomly assigned (1:1) to receive either protocol-guided individualised nutritional support to reach protein and caloric goals (intervention group) or standard hospital food (control group). Randomisation was done with variable block sizes and stratification according to study site and severity of malnutrition using an interactive web-response system. In the intervention group, individualised nutritional support goals were defined by specialist dietitians and nutritional support was initiated no later than 48 h after admission. Patients in the control group received no dietary consultation. The composite primary endpoint was any adverse clinical outcome defined as all-cause mortality, admission to intensive care, non-elective hospital readmission, major complications, and decline in functional status at 30 days, and it was measured in all randomised patients who completed the trial. This trial is registered with ClinicalTrials.gov, number NCT02517476.

FINDINGS: 5015 patients were screened, and 2088 were recruited and monitored between April 1, 2014, and Feb 28, 2018. 1050 patients were assigned to the intervention group and 1038 to the control group. 60 patients withdrew consent during the course of the trial (35 in the intervention group and 25 in the control group). During the hospital stay, caloric goals were reached in 800 (79%) and protein goals in 770 (76%) of 1015 patients in the intervention group. By 30 days, 232 (23%) patients in the intervention group experienced an adverse clinical outcome, compared with 272 (27%) of 1013 patients in the control group (adjusted odds ratio [OR] 0·79 [95% CI 0·64-0·97], p=0·023). By day 30, 73 [7%] patients had died in the intervention group compared with 100 [10%] patients in the control group (adjusted OR 0·65 [0·47-0·91], p=0·011). There was no difference in the proportion of patients who experienced side-effects from nutritional support between the intervention and the control group (162 [16%] vs 145 [14%], adjusted OR 1·16 [0·90-1·51], p=0·26).

INTERPRETATION: In medical inpatients at nutritional risk, the use of individualised nutritional support during the hospital stay improved important clinical outcomes, including survival, compared with standard hospital food. These findings strongly support the concept of systematically screening medical inpatients on hospital admission regarding nutritional risk, independent of their medical condition, followed by a nutritional assessment and introduction of individualised nutritional support in patients at risk.

FUNDING: The Swiss National Science Foundation and the Research Council of the Kantonsspital Aarau, Switzerland.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Schuetz P, Fehr R, Baechli V, et al. Individualised nutritional support in medical inpatients at nutritional risk: a randomised clinical trial. Lancet. 2019. PMID: 31030981. doi:10.1016/S0140-6736(18)32776-4

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。